ArticleDigestive diseases and sciences2026
Repression of Polycomb Group Factor 1 Inhibits EMT Progression in Colon Cancers Cells via Wnt/β-Catenin and PI3K/Akt/mTOR Signaling Pathway.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundThe study aimed to investigate polycomb group factor 1 (PCGF1) expression in colon cancer and its mechanism of action in the proliferation and migration of colon cancer cells.
methodIn this study, PCGF1 expression in colon cancer and the association between PCGF1 expression and the survival prognosis of patients with colon cancer were analyzed using the cancer genome atlas (TCGA) database. Furthermore, PCGF1 expression in normal colon epithelial cells and colon cancer cells was examined. A PCGF1 knockdown cell model was developed using HCT116 and HT29 cell lines. The effect of PCGF1 on cell proliferation was evaluated via CCK-8 and clone formation assays. In addition, the effect of PCGF1 on cell invasive and migratory abilities was explored via scratch and Transwell experiments, and the expression levels of EMT-related proteins was analyzed via immunoblotting assay.
resultsPCGF1 expression significantly increased in colon cancer tissues. This expression was also found to be closely associated with tumor staging of patients with colon cancer. High PCGF1 expression showed negative correlation with overall survival rate in these patients. The proliferative ability of HCT116 and HT29 cells knocked down by PCGF1 weakened, colony formation was reduced, and cell invasive and migratory capabilities diminished. Meanwhile, the expressions of EMT-related proteins, such as N-cadherin and Snail1, were remarkably downregulated in PCGF1 knockdown cells, whereas that of E-cadherin was significantly upregulated. Moreover, PCGF1 knockdown led to a strongly decrease in the phosphorylation levels of PI3K, Akt and mTOR proteins and in the levels of β-catenin and c-Myc.
conclusionPCGF1 may promote the proliferation and EMT process in HCT116 and HT29 cells by activating the Wnt/β-catenin and PI3K/Akt/mTOR signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.